First shipments of this new store branded product have been initiated and represents a first-to-market accomplishment for Perrigo and Allergan.
These products are packaged and marketed as store brands or retailer ‘own label’ brands and provide consumers a high-quality, value alternative to the Mucinex 1200mg extended-release product.
Mucinex 1200mg extended-release tablets (guaifenesin 1200mg extended-release tablets), indicated to relieve chest congestion and to break up mucus, making coughs more productive, produced sales of approximately $71 million through food, drug and mass merchants during that last twelve months.
Perrigo’s Chairman and CEO Joseph C. Papa said: "This product approval and launch demonstrates the power of matching Perrigo’s OTC platform with Allergan’s world-class generics R&D capabilities.
"Our teams together worked to bring this important product to our consumers and customers around the world. The Mucinex® family of products is an important offering to our customers and we look forward to launching the remaining products throughout 2016."
"Today’s launch of Mucinex 1200mg extended-release product underscores the power of bringing together two leading organizations in generic product development and OTC and store brand products to deliver high-quality, affordable medicines for patients around the world," said Robert Stewart, Allergan’s Executive Vice President & President, Generics and Global Operations.
"Perrigo has been an outstanding partner in bringing this and other Mucinex store brand products to market, and we look forward to our continued efforts to bring additional formulations of the Mucinex family of products forward for the patients and customers that we serve."